Filing Details

Accession Number:
0001181431-11-058766
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-12-05 16:17:40
Reporting Period:
2011-12-01
Filing Date:
2011-12-05
Accepted Time:
2011-12-05 16:17:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1325879 Aveo Pharmaceuticals Inc AVEO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1486519 Brannon David Johnston C/O Aveo Pharmaceuticals, Inc.
75 Sidney Street
Cambridge MA 02139
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-12-01 1,000 $5.60 7,000 No 4 M Direct
Common Stock Disposition 2011-12-01 1,000 $16.74 6,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right-to-buy) Disposition 2011-12-01 1,000 $0.00 1,000 $5.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
165,000 2017-10-31 No 4 M Direct
Footnotes
  1. The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2011.
  2. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.55 to $16.82, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
  3. The option vested as to 25% of the shares on October 31, 2008 and as to an additional 1/48 of the shares per month thereafter.